TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2522405

Group type: EXPERIMENTAL
Intervention: Low initial dosage of acitretin (10, 30, 50 mg/day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Constant dosage of acitretin (30 mg/day)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: High initial dosage of acitretin (50, 30, 10 mg/day)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: All groups (10, 30, or 50 mg/day) during open phase
Number of subjects: 66
Study: 30910964

Group type: EXPERIMENTAL
Intervention: Debt relief worth up to Singapore dollars 5,000 (∼3 month's household income)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Debt relief worth ∼1 month's household income
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Debt relief magnitude
Number of subjects: 196
Study: 28706106

Group type: EXPERIMENTAL
Intervention: Retrievable inferior vena cava (IVC) filter
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control (no IVC filter)
Number of subjects: 240
Study: 24906471

Group type: EXPERIMENTAL
Intervention: 5-methyltetrahydrofolate (5-MTHF) 15 mg/day for 3 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 23913405

Group type: EXPERIMENTAL
Intervention: Clopidogrel napadisilate 75 mg once daily
Number of subjects: 162

Group type: COMPARATOR
Intervention: Clopidogrel bisulfate 75 mg once daily
Number of subjects: 162
Study: 21871589

Group type: EXPERIMENTAL
Intervention: Denosumab 0.03, 0.1, 0.3, 1.0 or 3.0 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 18986507

Group type: EXPERIMENTAL
Intervention: Functional genomic analysis combined with expression or sequence analysis of genes and microRNAs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Microarray signatures
Number of subjects: 0
Study: 16439874

Group type: EXPERIMENTAL
Intervention: Therapeutic immunization with four boosts of ALVAC 1433 and HIV‐LIPO‐6T vaccines followed by three cycles of subcutaneous interleukin‐2
Number of subjects: 70

Group type: COMPARATOR
Intervention: Antiretroviral treatment alone (Control)
Number of subjects: 70
Study: 12627987

Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a (40kD) 180 microg once a week for 48 weeks (n = 267)
Number of subjects: 531

Group type: COMPARATOR
Intervention: Unmodified interferon alpha-2a 6 million IU three times a week for 12 weeks followed by 36 weeks of 3 million IU three times a week (n = 264)
Number of subjects: 531
Study: 10695888

Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen
Number of subjects: 51
Study: 9411672

Group type: EXPERIMENTAL
Intervention: Postoperative treatment with 500 mg of 17‐1A antibody, followed by four 100 mg infusions each month.
Number of subjects: 189

Group type: COMPARATOR
Intervention: Observation regimen (control group).
Number of subjects: 189
Study: 8249618

Group type: EXPERIMENTAL
Intervention: Nimodipine capsules (239 mumol)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Nimodipine tablets (239 mumol)
Number of subjects: 8
Study: 2871538

Group type: EXPERIMENTAL
Intervention: Levobunolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other beta-blockers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physiologic saline solutions
Number of subjects: 0
Study: 31025438

Group type: EXPERIMENTAL
Intervention: Targeted protein fortification
Number of subjects: 2

Group type: COMPARATOR
Intervention: Adjustable protein fortification
Number of subjects: 2
Study: 30251187

Group type: EXPERIMENTAL
Intervention: Unilateral incremental VOR adaptation training lasting 15 min with a 1:1 ratio of head impulses to each side.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Protocol two: VOR adaptation training with a 2:1 ratio of head impulses favoring the adapting side.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Protocol three: All head impulses towards the adapting side, training lasted 7.5 min.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Protocol four: All head impulses towards the adapting side, training lasted 15 min.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Protocol five: All head impulses to the adapting side, exposure time to the visual target during each impulse was doubled.
Number of subjects: 11
Study: 26222393

Group type: EXPERIMENTAL
Intervention: PDPH receiving a blood patch
Number of subjects: 10685

Group type: EXPERIMENTAL
Intervention: Cervix dilatation ≥7 cm
Number of subjects: 10685

Group type: EXPERIMENTAL
Intervention: Multiple punctures
Number of subjects: 10685

Group type: COMPARATOR
Intervention: Maternal Body Mass Index, age, mode of delivery, performance at night, level of needle insertion
Number of subjects: 10685

Group type: COMPARATOR
Intervention: Experience of the anesthesiologist
Number of subjects: 10685
Study: 25831694

Group type: EXPERIMENTAL
Intervention: Continuous epidural analgesia (E4) and sevoflurane anesthesia during surgery; continuous epidural analgesia with ropivacaine and fentanyl after surgery
Number of subjects: 350

Group type: COMPARATOR
Intervention: General anesthesia with sevoflurane and fentanyl; systemic administration of opioids after surgery
Number of subjects: 350
Study: 22181022

Group type: EXPERIMENTAL
Intervention: Therapist behavior similarity to supervisor
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Client behavior similarity to trainee
Number of subjects: 17
Study: 19131059

Group type: EXPERIMENTAL
Intervention: Serum IL‐18 levels in women with PCOS
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Carotid IMT in women with PCOS
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Hcy levels in women with PCOS
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CRP levels in women with PCOS
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: IL‐6 levels in women with PCOS
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: MDA levels in women with PCOS
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Homeostasis model assessment of insulin resistance in women with PCOS
Number of subjects: 120
Study: 17828627

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (5 g four times a day for 1 week, followed by the same dosage for the second week)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (5 g four times a day for 1 week, followed by the same dosage for the second week)
Number of subjects: 32
Study: 15668606

Group type: EXPERIMENTAL
Intervention: tibolone 2.5 mg/day
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg/day + MPA 5 mg/day
Number of subjects: 43
Study: 12186625

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg/day
Number of subjects: 1021

Group type: COMPARATOR
Intervention: Megestrol acetate 40 mg q.i.d.
Number of subjects: 1021

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 1021

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 1021
Study: 10024754

Group type: EXPERIMENTAL
Intervention: Flutter airway clearance device
Number of subjects: 15

Group type: COMPARATOR
Intervention: Chest physiotherapy (CPT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Vital Signs, Inc. 9000 PEP therapy
Number of subjects: 15
Study: 8834825

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1674677

Group type: EXPERIMENTAL
Intervention: Pancuronium (P) 0.08 mg.kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vecuronium (V) 0.1 mg.kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atracurium (A) 0.5 mg.kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Metocurine 0.1 mg.kg‐1 plus pancuronium 0.02 mg.kg‐1 (M-P)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (P group)
Number of subjects: 40
Study: 7016094

Group type: EXPERIMENTAL
Intervention: Glutathione-bicarbonate-Ringer's solution (BSS Plus)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 0
Study: 31353936

Group type: EXPERIMENTAL
Intervention: Parenting training program
Number of subjects: 178

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 178
Study: 31023525

Group type: EXPERIMENTAL
Intervention: Lifestyle-based T2D prevention recommendations including consumption of less than 25 g of sugar daily
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Reduction of daily sugar intake to less than 25 g
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: General lifestyle-based recommendations (including dairy, vegetables, and fruit consumption)
Number of subjects: 123
Study: 28340204

Group type: EXPERIMENTAL
Intervention: CO‐CUIDATE program (lumbopelvic stabilization program)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 46
Study: 26043591

Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine (Lbup)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine (Bup)
Number of subjects: 102

Group type: COMPARATOR
Intervention: 2% lidocaine with epinephrine 1:80,000 (Lid + Epi)
Number of subjects: 102
Study: 23579178

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Metformin (M)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sitagliptin (S)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Metformin + Sitagliptin (M+S)
Number of subjects: 16
Study: 21188440

Group type: EXPERIMENTAL
Intervention: Midazolam and Diclofenac (0.05 mg/kg midazolam and 1.5 mg/kg diclofenac, 15 min before surgical incision)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Diclofenac (1.5 mg/kg diclofenac, 15 min before surgical incision)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Midazolam and Diclofenac
Number of subjects: 90

Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 90
Study: 19395701

Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guided meditation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care services
Number of subjects: 0
Study: 17430327

Group type: EXPERIMENTAL
Intervention: Soda lime
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: DrägerSorb Free
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Amsorb Plus
Number of subjects: 15
Study: 14991551

Group type: EXPERIMENTAL
Intervention: Culturally competent intervention of education and care
Number of subjects: 25
Study: 12545682

Group type: EXPERIMENTAL
Intervention: Rheopheresis
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo-Control
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Rheopheresis (subgroup with baseline BCVA worse than 20/40)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo-Control (subgroup with baseline BCVA worse than 20/40)
Number of subjects: 43
Study: 9659700

Group type: EXPERIMENTAL
Intervention: 0.5 mg Dinoprostongel (Prepidil)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: 0.5 mg Sulprostongel (Nalador)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: 0.5 mg Dinoprostongel (repeated applications)
Number of subjects: 79

Group type: COMPARATOR
Intervention: 1 mg Gemeprost vaginal suppositories (Cergem)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Repeated therapy with Gemeprost
Number of subjects: 79
Study: 7697843

Group type: EXPERIMENTAL
Intervention: 90-micrograms/kg bolus of Integrelin followed by a 1.0-micrograms.kg-1.min-1 infusion for 4 hours
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 90-micrograms/kg bolus of Integrelin followed by a 1.0-micrograms.kg-1.min-1 infusion for 12 hours
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 2672841

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid for 7 days prior to lithotripsy
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid after lithotripsy
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Lithotripsy
Number of subjects: 81
Study: 330481

Group type: EXPERIMENTAL
Intervention: Pivmecillinam
Number of subjects: 243

Group type: COMPARATOR
Intervention: Amoxycillin
Number of subjects: 243
Study: 30686501

Group type: EXPERIMENTAL
Intervention: RCS training program
Number of subjects: 64
Study: 28394709

Group type: EXPERIMENTAL
Intervention: Fissure sealant (FS) applied to caries-free FPMs, maintained at 6-month intervals.
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (FV) applied at baseline and at 6-month intervals for 3 years.
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Fissure sealant (FS)
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (FV)
Number of subjects: 1016
Study: 25562575

Group type: EXPERIMENTAL
Intervention: Exercise trial (90 min of moderate-intensity treadmill running)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control trial (no exercise)
Number of subjects: 9
Study: 23315286

Group type: EXPERIMENTAL
Intervention: 0.1 l/min 100% oxygen
Number of subjects: 14

Group type: COMPARATOR
Intervention: 0.1 l/min air (21% oxygen)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham treatment (tubing disconnected from flow-meter)
Number of subjects: 14
Study: 20809272

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (22 mg/day as zinc gluconate) for 30 days
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (maltodextrin) for 30 days after zinc supplementation
Number of subjects: 7
Study: 19243768

Group type: EXPERIMENTAL
Intervention: Gross visual assessment by cytotechnologists
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Gross visual assessment by EUS technologists
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Routine practice of 6 to 7 FNA passes
Number of subjects: 51

Group type: COMPARATOR
Intervention: Rapid on-site cytopathology
Number of subjects: 51
Study: 16757446

Group type: EXPERIMENTAL
Intervention: Internet-based prevention program for eating disorders with discussion groups
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Internet-based prevention program for eating disorders without discussion groups
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study: 15326129

Group type: EXPERIMENTAL
Intervention: Dynamic Contour Tonometer (DCT)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Goldmann Applanation Tonometer (GAT)
Number of subjects: 228
Study: 11158071

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg twice daily
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 9243225

Group type: EXPERIMENTAL
Intervention: Midazolam (3.75 mg, 1/2 tablet Dormicum 7.5 mg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Midazolam (3.75 mg)
Number of subjects: 46
Study: 8481669

Group type: EXPERIMENTAL
Intervention: CI(idarubicin)OP
Number of subjects: 44

Group type: COMPARATOR
Intervention: CH(doxorubicin)OP
Number of subjects: 44
Study: 3627392

Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo transdermal patches
Number of subjects: 12
Study: 31954158

Group type: EXPERIMENTAL
Intervention: Vaginal 10-μg estradiol tablet
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Vaginal moisturizer
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study: 30033433

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 12521

Group type: EXPERIMENTAL
Intervention: Combination therapy (rosuvastatin + candesartan/hydrochlorothiazide)
Number of subjects: 12521

Group type: EXPERIMENTAL
Intervention: Candesartan/hydrochlorothiazide
Number of subjects: 12521

Group type: COMPARATOR
Intervention: Healthy lifestyles (≥2 factors)
Number of subjects: 12521
Study: 27044935

Group type: EXPERIMENTAL
Intervention: H‐RT (70 Gy in 28 fractions over 5.6 weeks)
Number of subjects: 1115

Group type: COMPARATOR
Intervention: C‐RT (73.8 Gy in 41 fractions over 8.2 weeks)
Number of subjects: 1115

Group type: EXPERIMENTAL
Intervention: H‐RT
Number of subjects: 1115
Study: 25403146

Group type: EXPERIMENTAL
Intervention: Standard monitoring and additional capnography (experimental group)
Number of subjects: 704

Group type: COMPARATOR
Intervention: Standard monitoring (control group)
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 704
Study: 23885609

Group type: EXPERIMENTAL
Intervention: Acupuncture at twelve meridians acupoints
Number of subjects: 80

Group type: COMPARATOR
Intervention: Clonazepam
Number of subjects: 80
Study: 19912212

Group type: EXPERIMENTAL
Intervention: Degarelix subcutaneous 240 mg for 1 month followed by monthly maintenance doses of 80 mg or 160 mg
Number of subjects: 610

Group type: COMPARATOR
Intervention: Leuprolide 7.5 mg/month
Number of subjects: 610
Study: 18564396

Group type: EXPERIMENTAL
Intervention: Platelet transfusions stored in plasma
Number of subjects: 117

Group type: COMPARATOR
Intervention: Platelet transfusions stored in PAS II
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Platelet transfusion failure
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Patients with one or more 24-hour PLT transfusion failures
Number of subjects: 117
Study: 15716891

Group type: EXPERIMENTAL
Intervention: Tranexamic acid mouthwash (TAMW)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Factor replacement therapy (FRT)
Number of subjects: 16
Study: 12798478

Group type: EXPERIMENTAL
Intervention: Doppler ultrasound umbilical artery flow velocity waveform analysis
Number of subjects: 526

Group type: COMPARATOR
Intervention: Standard ultrasound biometric assessment
Number of subjects: 526
Study: 11106131

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 31
Study: 9115560

Group type: EXPERIMENTAL
Intervention: Medical history analysis using the top 142 predicting questions
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Medical history analysis using the 30 strongest predictors
Number of subjects: 288

Group type: COMPARATOR
Intervention: Control group (normal knees)
Number of subjects: 288
Study: 1621239

Group type: COMPARATOR
Intervention: MF 701, 100 mg IM b.i.d. (first phase)
Number of subjects: 206

Group type: COMPARATOR
Intervention: MF 701, 300 mg IM b.i.d. (second phase)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo (first phase)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Both groups (MF 701 and placebo)
Number of subjects: 206
Study: 6391343

Group type: EXPERIMENTAL
Intervention: Wearing masks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Not wearing masks (Control)
Number of subjects: 41
Study: 29460440

Group type: EXPERIMENTAL
Intervention: Intensive outpatient program plus telephone-based continuing care intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intensive outpatient program alone
Number of subjects: 0
Study: 27763802

Group type: EXPERIMENTAL
Intervention: BMO‐30 (extract from Schisandra chinensis)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 25030779

Group type: EXPERIMENTAL
Intervention: Isomaltulose
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 11
Study: 22850440

Group type: EXPERIMENTAL
Intervention: Diagnostic mode
Number of subjects: 135

Group type: COMPARATOR
Intervention: Usual mode
Number of subjects: 135
Study: 20390482

Group type: EXPERIMENTAL
Intervention: Sexual risk-reduction intervention delivered in four sessions
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 270
Study: 18534218

Group type: EXPERIMENTAL
Intervention: Higher-dose indomethacin (0.2 or 0.5 mg/kg/d)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Low-dose indomethacin (0.1 mg/kg/d)
Number of subjects: 105
Study: 15755044

Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Number of subjects: 129

Group type: COMPARATOR
Intervention: GnRH agonist (leuprolide acetate)
Number of subjects: 129
Study: 14557467

Group type: EXPERIMENTAL
Intervention: oral glucose, iv octreotide
Number of subjects: 15

Group type: COMPARATOR
Intervention: oral glucose, iv saline
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: iv octreotide alone
Number of subjects: 15
Study: 11050700

Group type: EXPERIMENTAL
Intervention: Sustained release chitosan formulation of pentoxifylline
Number of subjects: 12

Group type: COMPARATOR
Intervention: Commercial formulation of pentoxifylline
Number of subjects: 12
Study: 8805732

Group type: EXPERIMENTAL
Intervention: White petrolatum
Number of subjects: 922

Group type: COMPARATOR
Intervention: Bacitracin
Number of subjects: 922
Study: 1515255

Group type: EXPERIMENTAL
Intervention: Alpha-2b interferon maintenance after double hemi-body irradiation
Number of subjects: 59

Group type: COMPARATOR
Intervention: Single hemi-body irradiation alone
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Double hemi-body irradiation with interferon
Number of subjects: 59

Group type: COMPARATOR
Intervention: Double hemi-body irradiation without interferon
Number of subjects: 59
Study: 6139745

Group type: EXPERIMENTAL
Intervention: Steroids and sulfasalazine (group A)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Elementary diet and sulfasalazine (group B)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Elementary diet with steroids and sulfasalazine (group C)
Number of subjects: 26
Study: 30562676

Group type: EXPERIMENTAL
Intervention: Women's Health CoOp Plus (WHC+)
Number of subjects: 641

Group type: COMPARATOR
Intervention: HIV counseling and testing (HCT)
Number of subjects: 641
Study: 29874528

Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 26707678

Group type: EXPERIMENTAL
Intervention: Stride length increased by +25%
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Stride length decreased by -25%
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (desired stride length)
Number of subjects: 19
Study: 25169211

Group type: EXPERIMENTAL
Intervention: Preventive health check (Intervention group)
Number of subjects: 10505

Group type: COMPARATOR
Intervention: Routine access to healthcare until a delayed intervention (Comparison group)
Number of subjects: 10505
Study: 22353644

Group type: COMPARATOR
Intervention: Adrenaline (1mg)
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: Vasopressin (40 IU)
Number of subjects: 727
Study: 20705796

Group type: EXPERIMENTAL
Intervention: Polysomnography (PSG) for diagnosis of OSA
Number of subjects: 165
Study: 17548410

Group type: EXPERIMENTAL
Intervention: Physiotherapist-directed advice
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Physiotherapist-directed exercise
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Combined exercise and advice
Number of subjects: 259